natgillin/translations-raw huggingface dataset:
is a hydrogen atom, an alkyl group having a carbon number of 1 to 6 optionally having substituent(s) or a C3-6 cycloalkyl group optionally having substituent(s); 
R* je atom vodika, alkilna skupina koja ima broj ugljika od 1 do 6 opcijski sa supstituentima ili je C34 cikloalkil- skupina koja opcijski ima supstituente;
Alternatively the active ingredients can be provided in the form of a dry powder, for example, a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP). 
Alternativno, aktivni sastojci se mogu osigurati u obliku suhog praha, na primjer, smjese praška spoja u prikladnoj praškastoj podlozi poput laktoze, škroba, derivata škroba poput hidroksipropilmetil celuloze i polivinilpirolidna (PVP).
The invention also relates to a pharmaceutical composition comprising an antibody of the invention and/or a conjugate thereof with a therapeutic agent, and a pharmaceutically acceptable carrier. 
Farmaceutska kompozicija koja sadrži antitijelo iz bilo kojeg od patentnih zahtjeva 1-9 i/ili konjugat iz patentnog zahtjeva 11,1 farmaceutski prihvatljiv nosač.
The method of claim 9, wherein R12 is selected from the group consisting of H and fluorine. The method of claim 1, wherein: 
Spoj prema zahtjevu 6, naznačen time da R5 je odabran iz skupine koja sadrži H, -C(=O)N(R9)2, te -CN.
aacacaaagtctacgcctgcgaagtcacccatcagggcctgagctcgcccgtcacaaagagcttcaacaggggagagt gttag [SEQ ID NO: 248] TABLE 7 shows exemplary nucleic acid sequences encoding heavy chain and light chain variable regions, in which the various CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 sequences are embedded. 
PATENTNI ZAHTJEVI 1. - Protutijelo, naznačeno time što se bira iz skupine koju čine protutijelo koje sadrži područja za određivanje komplementarnosti (CDR) CDRH1, CDRH2, CDRH3, CDRLI, CDRL2, te CDRL3, gdje navedeni CDR-i imaju aminokiselinske sljedove kao što su iznijeti niže:
Hc is selected from the group of tetrahydropyranyl and tetrahydrofuranyl, preferably 3- or 4-tetrahydropyranyl and 3-tetrahydrofuranyl. 
Hc je odabran iz skupine koju čine: 3- ili 4-tetrahidropiranil i 3-tetrahidrofuranil;
The compound for use according to claim 1 or claim 2, wherein testing comprises monitoring trough plasma levels of the compound in the subject for a period of at least ten weeks. 
Farmaceutski pripravak prema zahtjevu 1 ili zahtjevu 2, naznačen time da je barem 70% težinski soli u jednostrukom kristaliničnom obliku.
Results of the experiments showed that the tested compounds of the invention inhibit the serotonin and norepinephrine reuptake with IC50 below 200 nM. 
Rezultati eksperimenta pokazali su da testirani spojevi izuma inhibiraju re-apsorpciju serotonina i norepinefrina s ICso ispod 200 nM.
reducing Compound 21 to produce Compound 26: 
redukciji Spoja 21 [image] kako bi se dobilo Spoj 26:
Assessment of the Plasma Levels of Estriol 
Datum objave europske prijave patenta:
operating the winder spool (4, 5) of the winder unit to wind the wire (41) and thereby cut the bonding material, wherein during cutting wire is paid out from the dispenser unit to effect slip cutting of the bonding material. 
uporabu kalema za namatanje (4, 5) jedinice za namatanje za namatanje žice (41) i tako se izrezuje materijal za lijepljenje, pri čemu se tijekom izrezivanja žica izvlači iz jedinice za dovođenje da se postigne klizno rezanje materijala za lijepljenje.
The resulting mixture is stirred and allowed to warm to room temperature overnight. 
Dobivenu smjesu se miješa i pusti zagrijati na sobnu temperaturu preko noći.
ethylenediaminetetraacetic acid disodium salt dihydrate (EDTA) with the proviso that the composition in its ready-for-use formulation contains no more than 0.5% w/v of a metal halide salt. The composition according to claim 1 wherein the iota-carrageenan is present at a concentration in the range of from 0.2 to 0.4 % by weight. 
Jota- karagenan u antivirusno učinkovitoj količini za upotrebu u profilaktičkom ili terapeutskom topikalnom liječenju virusnih infekcija oka uzrokovanih adenovirusom podtipa D ili virusom A influence podtipa H7, uz ograničenje da pripravak u svojoj formulaciji spremnoj za primjenu sadrži ne više od 0.5 % w/v soli metalnog halogenida.
A method in accordance with any one of claims 1 to 10, wherein the subject is a human. 
Pripravak u skladu sa zahtjevom 1, naznačen time, da GPR119 agonist je agonist humanog GPR119.
adjusting such direct current component of the reference current up to a value in which the root-mean-square value of the sinusoidal component takes up the maximum value, 
namještanje komponente istosmjerne struje referentne struje do vrijednosti kod koje efektivna vrijednost sinusoidalne komponente zauzima maksimalnu vrijednost,
After cooling, 30% sodium hydroxide solution (97 ml) was added to the reaction mixture followed by 30% hydrogen peroxide solution (48.6 ml) and the reaction was stirred and heated to reflux for an additional 1 hour. 
Nakon hlađenja, u reakcijsku smjesu se doda 30%-tna otopina natrij hidroksida (97 ml) i neposredno nakon toga doda so i 30%-tna otopina vodikovog peroksida (48.6 ml) te se reakcija miješa i zagrijava do refluksa tijekom dodatnih sat vremena.
an HIC chromatogram in which (i) peak 3 is absent, or essentially absent and (ii) peak 2 represents greater than about 95 wt % of the composition; and 
(A) HIC kromatogram kod koga je (i) pik 3 odsutan, i (ii) pik 2 predstavlja više od 95 tež% kompozicije;
first frequency control means (40), for tuning the said local oscillator circuit (20) to the frequency of the said universal reference signal, and arranged to vary its oscillation frequency on the basis of the said determined frequency offset, in a first feedback slow control loop configuration; and 
- < prvi upravljački sklop za frekvenciju (40) za podešavanje spomenutog lokalnog oscilatorskog sklopa (20) sa prvom sporom upravljačkom strukturom povratne petlje, na frekvenciju spomenutog univerzalnog referentnog signala, pri čemu je tako raspoređen da mijenja svoju oscilacijsku frekvenciju na bazi spomenute određeno odlazne frekvencije; i
A concrete, mortar, grout or render comprising a cementitious binder as defined in any of clauses 1 to 11. 
Beton, žbuka, materijal za fugiranje ili materijal za žbukanje naznačen time što sadrži cementno vezivo kako je definirano u bilo kojem od zahtjeva 1 do 7.
Aerosol container according to Claim 5, wherein the RFID unit is in parallel orientation to the metal surface of the aerosol container. 
Spremnik aerosola u skladu sa zahtjevom 5, naznačen time, da je RFID jedinica paralelne orijentacije s metalnom površinom spremnika aerosola.
to 24 wt.-% polyethylene glycol, in particular polyethylene glycol having an average molecular weight of 4,000, based on the total weight of the composition. Pharmaceutical composition according to any one of the preceding claims wherein the quetiapine is in the form of quetiapine hemifumarate of crystalline form I of WO 03/080065 . 
12 do 24 %, težinski, polietilen-glikola, a osobito polietilen-glikola, prosječne molekulske težine od 4.000, na osnovu ukupne težine pripravka, Farmaceutski pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je kvetiapin u obliku kvetiapin-hemifumarata, u kristalnom obliku I iz dokumenta WO 03/080065.
A pharmaceutical composition, comprising a compound of claim 22 and a pharmaceutically acceptable carrier. 
Farmaceutski sastav, koji obuhvaća spoj prema bilo kojim zahtjevima 1 do 13 i farmaceutski prihvatljivi nosač.
The above precipitate was combined with the product from a second run starting with 0.15 mole 4-(3,4-dichlorophenyl)-3,4-dihydro-1-(2H)naphthalenone. 
Gornji talog se spoji sa proizvodom iz drugog eksperimenta koji polazi od 0.15 mola 4-(3,4-diklorofenil)-3,4-dihidro-2- (2H)-naftalenona.
constructing (S1120) a Most Probable Mode, MPM, group which is comprised of three intra prediction modes using the left intra prediction mode and the above intra prediction mode; 
konstruiranje (S1120) grupe najvjerojatnijih režima (MPM grupe) koja sadrži tri intrapredikcijska režima, a na osnovi lijevog intrapredikcijskog režima i gornjeg intrapredikcijskog režima;
A method according to any one of claims 7 and 8, wherein the ratio of aqueous solution such as water used in step (1) ranges from about 0.9 ml to about 4 ml aqueous solution /Nalmefene Hydrochloride (g), such as from about 1 ml to about 2 ml aqueous solution /Nalmefene Hydrochloride (g), more preferably 1.5 ml aqueous solution / Nalmefene Hydrochloride (g). 
Postupak prema bilo kojem od zahtjeva 7 i 8, gdje je omjer vodene otopine, kao što je voda, u koraku (1) u rasponu od oko 0.9 ml do oko 4 ml vodene otopine /Nalmefen hidroklorid (g), od oko 1 ml do oko 2 ml vodene otopine /Nalmefen hidroklorid (g), poželjnije 1.5 ml vodene otopine / Nalmefen hidroklorid (g).
In formulae (Ib) and (Ic), p preferably represents an integer of 2 to 3. 
(VID) p predstavlja cijeli broj od 0 do 3, q predstavlja cijeli broj od 0 do 1,
at least one cellulose ether; and at least one disintegrant; and at least one pharmaceutically acceptable active principle, for the manufacture of a formulation for the treatment of female genital disorders, wherein the at least one disintegrant is selected from modified celluloses such as cross-linked sodium carboxymethylcellulose, cross-linked polyvinylpyrrolidone such as crospovidone, natural starches such as maize starch, potato starch, directly compressible starches, modified starches such as carboxymethylstarches and sodium starch glycolate, starch derivatives such as amylose, alginic acid and sodium alginate, microcrystalline cellulose and wherein said female genital disorders are genital hypotrophy, genital atrophy, genital loss of elasticity, vaginal dryness, cervical and/or vaginal infections caused by fungi, bacteria, protozoa or viruses. 
Cc) najmanje jednog sredstva za raspadanje; te od najmanje jednog farmaceutski prihvatljivog aktivnog principa, naznačena time što je navedeni hidrofilni matriks namijenjen proizvodnji formulacije za liječenje ženskih genitalnih poremećaja, gdje najmanje jedno sredstvo za raspadanje se bira između modificiranih celuloza, poput umrežene natrij-karboksimetilceluloze, umreženog polivinilpirolidona, poput krospovidona, prirodnih škrobova, poput kukuruznog škroba, krumpirovog škroba, izravno kompresibilnih škrobova, modificiranih škrobova, poput karboksimetilškrobova i natrij-karboksimetilškroba, škrobnih derivata, poput amiloze, alginske kiseline i natrijevog alginata, mikrokristalne celuloze, te gdje navedeni ženski genitalni poremećaji su hipotrofija spolnih organa, atrofija spolnih organa, gubitak elastičnosti spolnih organa, suhoća rodnice, infekcije vrata maternice i/ili rodnice uzrokovane gljivicama, bakterijama, protozoama ili virusima.
A compound of formula (I), or salt, solvate, hydrate or prodrug thereof, wherein: 
-=veonamnavn -o Spoj s formulom (1), ili njegova sol, naznačen time da:
Check phase EV1) There are several nodes having Eced(if)>Erich(if): if (yes) it accesses E1, if (no) it accesses E4; 
Kontrolna faza EV1) postoji nekoliko čvorova koji imaju Eced(if) > Erich(if): ako (da) pristupa E1, ako (ne) pristupa E4;
On the inner side there is a passage 45 with a small diameter, while in the vicinity of the free end 38, as in the embodiment described above, there ate openings 36 and 37, the openings 37 being used to discharge flushing liquid. 
Na njegovoj unutarnjoj strani se nalazi prolaz 45 koji ima mali promjer, dok se u blizini slobodnog kraja 38, kao što je to opisano za gore navedeno ostvarenje, nalaze otvori 36 i 37, pri čemu se otvori 37 koriste za ispuštanje tekućine za ispiranje.
Postitive control wells contain no inhibitor. 
Jažice za pozitivnu kontrolu ne sadrže inhibitor.
The choice of an emulsifier is well within ordinary skill in the art and is not a critical aspect of the invention. 
Izbor emulgatora ovisi o stručnjaku područja i nije presudan aspekt izuma.
Element according to claim 2, characterized in that it comprises a first elastic band (24), arranged to cross said free area (23) and connecting each other said arc shaped portions (22A), (22B). 
Element u skladu s patentnim zahtjevom 2, naznačen time, da sadržava prvu elastičnu traku (24), koja je postavljena tako da prelazi navedenu slobodnu površinu (23) 1 međusobno povezuju navedene dijelove u obliku luka (22A), (22B).
The shaped article according to claim 1, wherein the elastomeric material contains 1 to 100 phr, preferably 3 to 75 phr, more preferably 5 to 60 phr, of resin (B), based on 100 phr of elastomeric polymer (A). 
Oblikovani članak (100) prema patentnom zahtjevu 1, pri čemu elastomerni materijal sadrži 1 do 100 phr, poželjno 3 do 75 phr, poželjnije 5 do 60 phr, smole (B), bazirano na 100 phr elastomernog polimera (A).
Compound 53 was obtained as a brown solid. 
Spoj 53 se dobiva kao smeđa krutina.
a comparatively thick cable that supports, and sometimes conveys data transmission cables to, the downhole toolstring) to pass through a narrowed or deviated portion of the wellbore, and subsequently become stuck at that location as the wireline is being wound into a surface location to withdraw the toolstring. 
debelog kabla koji nosi i ponekad prenosi kabel za prijenos podataka, a i spušta alat) treba proći kroz uski ili zakrivljeni dio bušotine i tu se zaglavljuje u položaju, jer žičana veza postaje zaglavljena u površinskom položaju da bi se izvukao alat.
modulating the signal frame by an Orthogonal Frequency Division Multiplexing, OFDM, method; and transmitting the modulated signal frame, 
moduliranje (S1705) okvira signala pomoću OFDM metode; i odašiljanje (S1707) moduliranog okvira signala.
Said high intensity sweetener is preferably selected from the group consisting of acesulfame K, neohesperidine DC, aspartame, neotame, saccharin, sucralose or can be a combination thereof. 
Prednost se daje tome da se rečeno sladilo velike slatkoće bira iz skupine koju čine acesulfam K, neohesperidin DC, aspartam, neotam, saharin, sukraloza, alitam, taumatin, ciklamat, glikorizin, ili njihove kombinacije.
each R3 is independently selected from hydroxy, halogen, cyano, NH2, C1 alkyl optionally substituted with halogen or C1 alkyloxyl, or C2 alkynyl; and n is an integer selected from 0 or 1. 
je alkil, alkenil, alkinil, aril, aralkil, karbociklil, heterociklil, heteroaril, karbociklilalkil, heterociklilalkil ili heteroarilalkil; i n je cijeli broj obabran od 0 ili 1.
An antibody or a functional fragment thereof according to any one of claims 1 to 7 for use in increasing at least one of bone mass, bone mineral density, bone mineral content, or bone strength in a human subject. 
Protutijelo, ili njegov funkcionalni fragment, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačeno time što je namijenjeno upotrebi u povećavanju najmanje jednog od koštane mase, mineralne gustoće kostiju, mineralnog sadržaja kostiju ili čvrstoće kostiju kod ljudskog subjekta.
These compositions are suitable for pharmaceutical use, as shown by the PROLEUKIN™ product. 
Ovi su sastavi prikladni za farmaceutsku uporabu, kako je prikazano proizvodom PROLEUKINTM,
According to one embodiment the slurry comprises further minerals containing magnesium, potassium or sodium, preferably magnesium carbonate, calcium magnesium carbonate, e.g. dolomitic limestone, calcareous dolomite, dolomite or half-burnt dolomite; magnesium oxide such as burnt dolomite, magnesium sulfate, potassium hydrogen carbonate, or sodium hydrogen carbonate. 
Postupak prema bilo kojem od prethodnih zahtjeva, pri čemu mulj sadrži daljnje minerale koji sadrže magnezij, kalij ili natrij, poželjno magnezij karbonat, kalcij magnezij karbonat, poput dolomitskog vapnenca, vapnenačkog dolomita, dolomita ili polu-spaljenog dolomita, magnezij oksid poput spaljenog dolomita, magnezij sulfat, kalij hidrogen karbonat, ili natrij hidrogen karbonat.
A composition for controlling an invertebrate pest comprising a biologically effective amount of the mixture of Claim 1 or Claim 2 and at least one additional component selected from the group consisting of a surfactant, a solid diluent and a liquid diluent, said composition optionally further comprising an effective amount of at least one additional biologically active compound or agent. 
Metoda iz bilo kojeg od patentnih zahtjeva 1 do 3, gdje smjesa dodatno obuhvaća barem jednu od tvari odabranu iz skupine koja se sastoji od sufraktanta, čvrstog diluenta i tekućeg diluenta, navedeni sastav po izboru nadalje sadržava učinkovitu količinu barem jedne dodatne biološki aktivne tvari ili agensa.
The ophthalmic preparation according to claim 1, comprising a saline solution as pharmaceutically acceptable carrier. 
Oftalmološki pripravak prema patentnom zahtjevu 1 ili 2, naznačen time da je sadrži otopinu soli kao farmaceutski prihvatljiv nosač.
An antifoaming agent eliminates the delay and is employed primarily as a matter of production expediency. 
Sredstvo protiv stvaranja pjene eliminira odlaganje i primarno se koristi radi ubrzavanja.
An anti-N3pGlu AB antibody or antigen-binding fragment thereof for use in the prevention of a condition selected from clinical or pre-clinical Alzheimer's disease, prodromal Alzheimer's disease, and clinical or pre-clinical CAA, wherein the antibody or antigen-binding fragment thereof comprises a light chain variable region (LCVR) and a heavy chain variable region (HCVR), wherein said LCVR comprises LCDR1, LCDR2, and LCDR3 polypeptides and HCVR comprises HCDR1, HCDR2, and HCDR3 polypeptides which are selected from the group consisting of: 
Protutijelo protiv N3pGlu AB, ili njegov antigenski vežući fragment, namijenjeno upotrebi u skladu s patentnim zahtjevom 1 ili namijenjeno upotrebi u skladu s patentnim zahtjevom 2, naznačeno time što protutijelo, ili njegov antigenski vežući fragment, sadrži varijabilno područje lakog lanca (LCVR) i varijabilno područje teškog lanca (HCVR), gdje navedeni LCVR sadrži polipeptide LCDR1, LCDR2, te LCDR3, a HCVR sadrži polipeptide HCDR1, HCDR2, te HCDR3, koje se bira iz skupine koju čine:
MI is a transition metal of group IB, or group 11 in the IUPAC nomenclature, MIII is a transition metal of group IIIA, or group 13 in the IUPAC nomenclature, AVI is a chalcogen of group VIA, or group 16 in the IUPAC nomenclature. 
M je prijelazni metal iz skupine Ig, ili skupine 11 u IUPAC-ovoj nomenklaturi, M" je prijelazni metal iz skupine TIL, ili skupine 13 u IUPAC-ovoj nomenklaturi, AX je halkogen iz skupine VI, ili skupine 16 u IUPAC-ovoj nomenklaturi.
substitution of amino acid 951: in protein E2; threonine to isoleucine. 
supstituciju aminokiseline 951; u proteinu E2; izoleucinom. 5.
Composition for use according to claims 1 or 2, characterized in that the composition comprises an effective amount of 24-nor-ursodeoxycholic acid, pharmaceutically acceptable salts or esters thereof and at least one pharmaceutically acceptable carrier and/or excipient. Composition for use according to any one of claims 1 to 3, characterized in that the composition comprises 10 to 8000 mg, preferably 25 to 5000 mg, more preferably 50 to 1500 mg, in particular 250-500 mg, of 24-nor-ursodeoxycholic acid and/or at least one pharmaceutically acceptable salt and/or ester thereof. 
Nor-ursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, koje se upotrebljavaju za liječenje i/ili prevenciju hepatocelularnog karcinoma i kolangiokarcinoma, prema zahtjevima 1 ili 2, naznačene time, da se norursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, primjenjuju na pacijentu u dnevnoj količini od 25 mg do 5 g, poželjno od 100 mg do 2,5 g, posebno od 800 mg do 1,5 g.
A common problem of the prior art methods for preparing venlafaxine hydrochloride is the change of the polymorphic form of the active ingredient. 
Uobičajeni problem kod postupaka dobivanja venlafaksin-hidroklorid iz prethodnog stanja tehnike je promjena polimorfnog oblika aktivnog sastojka.
A pharmaceutical composition comprising a compound as defined in claim 1 and an inert, non-toxic, pharmaceutically suitable excipient. 
Medicinski proizvod koji sadrži spoj kako je definiran u zahtjevu 1, naznačen time da je u kombinaciji sa inertnom, ne-toksičnom, farmaceutski pogodnom pomoćnom tvari.
After this time, the solution was cooled to RT. 
Nakon ovog vremena otopina je ohlađena na sobnu temperaturu.
said concentrator (C) communicates with said plurality of remote meters (RM) in order to collect consumption related data and perform tasks concerning the administration of its associated remote meters, and 
- navedeni sabirnik (C) je povezan s navedenim velikim brojem daljinskih brojača (RM) kako bi prikupio podatke vezane uz potrošnju i obavio zadatke vezano uz upravljanje s njim povezanih daljinskih brojača i
In one embodiment, the pharmacologically active agent is selected from the group consisting of an scFv molecule, a Fab molecule, and a single domain antibody. 
Vezivna molekula u skladu s patentnim zahtjevom 13, naznačena time što se farmakološki aktivno sredstvo bira iz skupine koju čine molekula scFv, molekula Fab, te jednodomensko protutijelo.
Wind system (1) according to claim 4, characterised in that said systems that actuate said spoiler are piezoelectric. 
Vjetreni sustav (1) prema zahtjevu 14, naznačen time da spomenuti prijenosni sustav uključuje:
buprenorphine disposed in a mucoadhesive polymeric diffusion environment, wherein the mucoadhesive polymeric diffusion environment is a buffered environment having a pH between 4 and 6.5; and a barrier environment disposed relative to the mucoadhesive polymeric diffusion environment such that a unidirectional gradient is created upon application to a mucosal surface. 
buprenorfin odložen u mukoadhezivni polimerni difuzijski okoliš, pri čemu je mukoadhezivni polimerni difuzijski okoliš puferirani okoliš koji ima pH između 4 i 6.5; i granični okoliš odložen u odnosu na mukoadhezivni polimerni difuzijski okoliš tako da se stvara jednosmjerni gradijent nakon primjene na površinu mukoze.
In that case, the first instrument may comprise a lens and second instrument may comprise a needle to be introduced to the tissue, the needle being guided into the second guiding passage upon introducing the tubular member into the bladder through the urethra. 
U tom slučaju može prvi instrument imati iglu koju se treba uvesti u tkivo, pri čemu se igla vodi kroz drugi prolaz za vođenje za vrijeme uvođenje cijevnog elementa u mokraćni mjehur kroz mokraćnu cijev.
The lines of magnetic field, according to the definition, radiate out of the North pole (N) and into the South pole (S). 
Silnice magnetskog polja, po definiciji se šire iz sjevernog pola (N) HR P20080314 T3 prema južnom polu (S).
The composition according to claim 11, additionally comprising an additional therapeutic agent selected from an antibiotic, an anti-inflammatory agent, a matrix metallaprotease inhibitor, a lipoxygenase inhibitor, a cytokine antagonist, an immunosuppressant, an anti-cancer agent, an anti-viral agent, a cytokine, a growth factor, an immunomodulator, a prostaglandin, an anti-vascular hyperproliferation compound, or an agent which increases the susceptibility of bacterial organisms to antibiotics. 
Sastav prema zahtjevu 11, naznačen time da nadalje sadrži dodatno terapeutsko sredstvo odabrano od antibiotika, protuupalnog sredstva, inhibitora matriksa metaloproteaze, inhibitora lipoksigenaze, antagonista citokina, imunosupresanta, protutumorskog sredstva, sredstva protiv virusa, citokina, faktora rasta, imunomodulatora, prostaglandina, spoja protiv vaskularne hiperproliferacije, ili sredstva koje povećava osjetljivost bakterijskih organizama na antibiotike.
Use or pharmaceutical composition for use according to claim 7, wherein the X-Rays radiations are of about 50 KeV to 6000 KeV. 
. Uporaba farmaceutskog sastava za uporabu u skladu s patentnim zahtjevom 7, pri čemu su zračenja X-zraka oko 50